Kalshi, Polymarket Face Criticism for Clinical Trial Betting
Prediction platforms Kalshi and Polymarket are offering bets on clinical trial outcomes, drawing sharp criticism from ethicists and researchers. Critics describe the practice as "ghastly," arguing it commodifies patients' health and could create perverse incentives around medical research. The controversy highlights the growing tension between financial speculation and ethical oversight in healthcare.